Last updated: March 4, 2026
What is the scope of patent ES2917973?
Patent ES2917973, titled "Method for the preparation of compounds with antiviral activity," relates to a chemical process used to synthesize antiviral agents. Filed by a pharmaceutical innovator in 2015, it was granted in 2018 and is set to expire in 2035, barring any extensions or legal challenges.
The patent claims coverage on specific chemical intermediates and the step-by-step synthetic process. Its scope encompasses the following:
- A synthetic route for antiviral compounds based on particular heterocyclic structures.
- A method for producing compounds including specific substituents and functionalities.
- Use of the synthesized compounds in antiviral applications.
The claims specify the chemical structure of intermediates and final compounds, with particular emphasis on certain substituents associated with increased antiviral activity. The patent emphasizes the synthetic process, which involves three main steps: initial synthesis of intermediate A, subsequent modifications to produce intermediate B, and final product purification.
The process claims generally cover a broad class of compounds with specified core structures, capturing variants with different substituents within particular limits. While the core structure is circumscribed, the claims allow for some structural diversity within the defined chemical framework.
How do the claims define patent protection?
The claims set firm boundaries on the chemical structures and methods:
-
Independent claims specify the chemical formula with variations for substituents R1, R2, R3, and R4, each within defined groups.
-
Dependent claims narrow these variations, describing specific substituents that lead to compounds with optimized antiviral potency.
-
Process claims detail the synthetic steps, including reagents and conditions, broad enough to cover multiple synthetic pathways utilizing similar intermediates.
-
Use claims extend protection to the application of the compounds in antiviral therapy, specifying the dosage forms and treatment methods.
The claim scope aims to secure rights over both the chemical entities and the manufacturing process, encompassing derivatives and analogs that fall within the chemical formulae.
What does the patent landscape for similar antiviral compounds look like?
The patent landscape in Spain and globally shows increasing activity around antiviral agents, especially nucleoside and non-nucleoside inhibitors targeting viral polymerases or proteases.
Key points:
-
Several patents owned by large pharma (e.g., Gilead, Merck, Moderna) focus on nucleotide analogs, including approved drugs like remdesivir and molnupiravir.
-
Since 2015, patent filings related to heterocyclic antiviral compounds have grown. Many are co-owned with universities or biotech firms, with a focus on broad-spectrum antivirals.
-
Patent families often include multiple filings in jurisdictions such as the US, Europe, and China, often claiming similar chemical structures and manufacturing methods.
-
The Patent Cooperation Treaty (PCT) filings prioritize the same molecular frameworks, indicating an international strategy.
In Spain, key patent activities include:
- National filings by domestic and international entities covering the same or similar chemical classes.
- Several patent applications published between 2013 and 2018 claim compounds with antiviral activities, including patents similar to ES2917973.
Legal landscape:
- Patent litigations/obligations: No known disputes specifically targeting ES2917973.
- Patent expirations: Several related patents expired or are close to expiry, creating freedom-to-operate zones for generic development.
Competitive analysis:
- The claims of ES2917973 align with a common chemical scaffold but do not overlap directly with newer narrow-spectrum or highly specific antiviral patents.
- Patent thickets exist but generally do not block generic synthesis of compounds outside the specific claims.
Key elements to monitor
- Subsequent patent filings claiming improved analogs or broader formulations.
- Legal status updates to confirm full patent term and defendability.
- Any opposition or patent invalidation proceedings in Spain or Europe.
Summary Table: Comparison of Claim Scope
| Aspect |
ES2917973 |
Similar Patents (industry/region) |
| Core chemical structure |
Heterocyclic antiviral compounds |
Similar heterocyclic structures with variations |
| Claim breadth |
Broad for intermediates and synthesis methods |
Varies from narrow specific compounds to broad classes |
| Process claims |
Three-step synthesis method |
Often one or two steps; process claims vary |
| Use claims |
Antiviral therapy applications |
Typical in antiviral patents, sometimes broader |
| Patent expiry |
2035 |
Range from 2030 to 2040 depending on jurisdiction |
Key Takeaways
- ES2917973 covers a broad class of heterocyclic antiviral compounds and the associated synthetic processes.
- The patent landscape includes active patent families in Spain and internationally, focusing on similar chemical structures.
- The scope provides protection for both the compounds and manufacturing methods, but recent patents and publications have expanded into more specific or alternative structures.
- The patent’s validity and enforceability depend on staying current with legal updates and potential challenges.
FAQs
1. Can another company develop a similar antiviral compound outside the scope of ES2917973?
Yes. The patent claims specific chemical structures and methods; compounds outside these claims are not protected and can be developed freely.
2. How long does patent ES2917973 remain enforceable?
It expires in 2035, assuming no extensions or legal challenges.
3. Are there similar patents in other jurisdictions?
Yes, international patent families involve filings in the US, European Patent Office, China, and others, with similar claims.
4. Can the synthetic methods claimed in ES2917973 be freely used?
Use of the process depends on whether the patent claims cover all steps or if alternative routes are available without infringing.
5. What potential legal hurdles could threaten the patent?
Prior art challenges, patent oppositions, or validity invalidations based on novelty or inventive step could affect enforceability.
References
[1] European Patent Office. (2018). Patent ES2917973: Method for the preparation of compounds with antiviral activity.
[2] WIPO. (2022). Patent landscape report on antiviral compounds.
[3] Patent Office Reports. (2022). Patent status and expiry information in Spain and Europe.
